PHOSPHODIESTERASE-5 INHIBITORS USE IN PATIENTS WITH ERECTILE DYSFUNCTION AND CARDIOVASCULAR DISEASE IN CLINICAL PRACTICE

PHOSPHODIESTERASE-5 INHIBITORS USE IN PATIENTS WITH ERECTILE DYSFUNCTION AND CARDIOVASCULAR DISEASE IN CLINICAL PRACTICE

About 150 million men worldwide and about 50% of men aged 40-88 y.o. in outpatient practice suffer from erectile dysfunction (ED). There is a linear relation between the age and ED rate. The main reason of ED in the majority of men (about 80% of patients) is cardiovascular diseases (atherosclerosis,...

Full description

Bibliographic Details
Main Authors:	M. N. Mamedov, G. G. Sharvadze, E. A. Poddubsky, A. K. Ausheva
Format:	Article
Language:	English
Published:	Столичная издательская компания 2016-01-01
Series:	Рациональная фармакотерапия в кардиологии
Subjects:	erectile dysfunction cardiovascular disease phosphodiesterase-5 inhibitors
Online Access:	https://www.rpcardio.online/jour/article/view/969

Similar Items

Endothelial Dysfunction, Erectile Dysfunction and Phosphodiesterase 5 Inhibitors. An Update of the Current Data and Future Perspectives
by: Angelis Konstantinopoulos, et al.
Published: (2007-01-01)

Phosphodiesterase type 5 inhibitors as treatment for erectile dysfunction: a webinar-based poll unveiling perceptions of healthcare professionals
by: Maher S Moazin, et al.
Published: (2024-05-01)

Phosphodiesterase-5 inhibitors for erectile function rehabilitation in patients undergoing nerve sparing radical prostatectomy: a scoping review
by: GABRIEL CARVALHO ANDRADE GADELHA, et al.
Published: (2024-11-01)

MANAGEMENT OF ERECTILE DYSFUNCTION IN CARDIOVASCULAR PATIENTS WITH COMORBIDITIES: REVIEW OF THE TRIALS ON CONTINUING THERAPY WITH PHOSPHODIESTERASE-5 MEDICATIONS
by: G. G. Sharvadze, et al.
Published: (2018-06-01)

An open-label, multicenter, randomized, crossover study comparing sildenafil citrate and tadalafil for treating erectile dysfunction in Chinese men naïve to phosphodiesterase 5 inhibitor therapy
by: Wen-Jun Bai, et al.
Published: (2015-02-01)

Exercise training improves erectile dysfunction (ED) in patients with metabolic syndrome on phosphodiesterase-5 (PDE-5) inhibitors
by: Luigi Maresca, et al.
Published: (2013-12-01)

Pathophysiology of visual disorders induced by phosphodiesterase inhibitors in the treatment of erectile dysfunction
by: Moschos MM, et al.
Published: (2016-10-01)

Inflammatory biomarkers may predict response to phosphodiesterase type 5 inhibitor treatment in patients with erectile dysfunction
by: Metin Kilic, et al.
Published: (2023-07-01)

Erectile dysfunction in patients taking psychotropic drugs and treated with phosphodiesterase-5 inhibitors
by: Rossella Mazzilli, et al.
Published: (2018-03-01)

The pharmacological management of erectile dysfunction
by: Andre Marais
Published: (2015-07-01)

A meta-regression evaluating the effectiveness and prognostic factors of oral phosphodiesterase type 5 inhibitors for the treatment of erectile dysfunction
by: Jin-Qiu Yuan, et al.
Published: (2016-01-01)

Phosphodiesterase-5 inhibitors for erectile dysfunction in patients with diabetes mellitus: A systematic review and meta-analysis of randomized controlled trials
by: Yatan Pal Singh Balhara, et al.
Published: (2015-01-01)

The pharmacological management of erectile dysfunction – Update 2016
by: André Marais
Published: (2016-08-01)

Investigation of Cnidium monnieri compounds as phosphodiesterase-5 antagonists in erectile dysfunction via molecular docking and dynamic simulation
by: Damilola Alex Omoboyowa
Published: (2024-01-01)

Obesity and Erectile Dysfunction: From Bench to Clinical Implication
by: Ki Hak Moon, et al.
Published: (2019-05-01)

Expectations do not Influence the Response to Phosphosdiesterase Type 5 Inhibitor Therapy for Erectile Dysfunction
by: Connie C. J. Louizos, et al.
Published: (2015-11-01)

Mechanisms of L-citrulline on phosphodiesterase 5 in erectile dysfunction intervention
by: Abdulhakeem Olarewaju Sulyman, et al.
Published: (2025-03-01)

Influence of regular use of vardenafil on endothelial and erectile functions in patients with arteriogenic erectile dysfunction
by: Safar Israilovich Gamidov, et al.
Published: (2009-10-01)

Effect of phosphodiesterase type 5 inhibitors on sperm motility and acrosome reaction: An in vitro study
by: Seung-Hun Song, et al.
Published: (2021-05-01)

Influence of personality disorders on sexual behaviours and response to treatment of psychogenic erectile dysfunction in phosphodiesterase 5 inhibitor non-responders
by: Marina Cabello-García, et al.
Published: (2024-10-01)

Erectile dysfunction in diabetes mellitus: A review
by: Deepak K Jumani, et al.
Published: (2020-01-01)

Sildenafil Citrate Oral Suspension for Managing Erectile Dysfunction: A Systematic Review and a Consensus Report from the Italian Society of Andrology (SIA)
by: Carlos Miacola, et al.
Published: (2024-08-01)

Evolution of phosphodiesterase type 5 inhibitors in treatment of erectile dysfunction in Taiwan
by: Bang-Ping Jiann
Published: (2016-06-01)

Could erectile dysfunction be a marker of atherosclerotic cardiovascular disease?
by: G. G. Sharvadze, et al.
Published: (1970-01-01)

Postprostatectomy Erectile Dysfunction: A Review
by: Paolo Capogrosso, et al.
Published: (2016-08-01)

Pharmacotherapy of erectile dysfunction: Current standards
by: Kew-Kim Chew
Published: (2006-01-01)

Does the Daily Dose of Tadalafil for the Treatment of Erectile Dysfunction Increase Penile Sensation?
by: Selim Taş, et al.
Published: (2023-03-01)

Peyronie′s disease and erectile dysfunction: Current understanding and future direction
by: Laurence A Levine
Published: (2006-01-01)

Gosha-Jinki-Gan Improved Erectile Dysfunction Caused by Anti-Cancer Agent Oxaliplatin by Decreasing Transcriptional Expression of Phosphodiesterase-5 in Rats
by: Tomoya Kataoka, PhD, et al.
Published: (2022-04-01)

Pathological Significance of Macrophages in Erectile Dysfunction Including Peyronie’s Disease
by: Yasuyoshi Miyata, et al.
Published: (2021-11-01)

Advancements in Phosphodiesterase 5 Inhibitors: Unveiling Present and Future Perspectives
by: Ahmed K. ElHady, et al.
Published: (2023-09-01)

Molecular and Histologic Evidence of Novel Erectile Dysfunction Rat Model as an Aging Atherosclerosis Model: A Preliminary Study
by: Jae Heon Kim, et al.
Published: (2020-07-01)

Efficacy and safety of short- and long-term, regular and on-demand regimens of phosphodiesterase type 5 inhibitors in treating erectile dysfunction after nerve-sparing radical prostatectomy: a systematic review and meta-analysis
by: Tian D, et al.
Published: (2017-02-01)

EDEUS, a Real-Life Study on the Users of Phosphodiesterase Type 5 Inhibitors: Prevalence, Perceptions, and Health Care-Seeking Behavior Among European Men With a Focus on 2nd-Generation Avanafil
by: Giovanni Corona, MD, PhD, et al.
Published: (2018-03-01)

Phosphodiesterase-5 Inhibitor Use in Robot Assisted Radical Prostatectomy Patients Is Associated with Reduced Risk of Death: A Propensity Score Matched Analysis of 1,058 Patients
by: Jongsoo Lee, et al.
Published: (2023-10-01)

Adherence to Phosphodiesterase Type 5 Inhibitors in the Treatment of Erectile Dysfunction in Long-Term Users: How Do Men Use the Inhibitors?
by: Ana Carvalheira, PhD, et al.
Published: (2014-06-01)

Effects of different treatments on endothelial function in patients with erectile dysfunction and hypogonadism
by: E B Mazo, et al.
Published: (2008-12-01)

REVITALISE: A Large Observational Study Assessing the Safety and Effectiveness of Vardenafil in Men With Erectile Dysfunction and Metabolic Syndrome
by: Ridwan Shabsigh, MD, FACS, et al.
Published: (2016-09-01)

Recreational use of oral erectile dysfunction medications among male physicians - A cross-sectional study
by: Raed Almannie, et al.
Published: (2023-01-01)

Relationship between Response to PDE5 Inhibitors and Penile Duplex Doppler Ultrasound in Erectile Dysfunction
by: Ercan Ogreden, et al.
Published: (2018-03-01)